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Periodontitis is an inflammatory disease characterized by periodontal pocket formation and alveolar bone resorption. Periodontal
bone resorption is induced by osteoclasts and receptor activator of nuclear factor-𝜅B ligand (RANKL) which is an essential and
central regulator of osteoclast development and osteoclast function. Therefore, RANKL plays a critical role in periodontal bone
resorption. In this review, we have summarized the sources of RANKL in periodontal disease and explored which factors may
regulate RANKL expression in this disease.
1. Introduction
Periodontitis is an inflammatory disease characterized by
periodontal pocket formation and alveolar bone resorption,
and it is one of the most common chronic inflammatory
diseases in aged populations. Porphyromonas gingivalis (P.
gingivalis), Actinobacillus actinomycetemcomitans (A. actino-
mycetemcomitans), andTreponemadenticola (T. denticola) are
major periodontal pathogens involved in various forms of
periodontitis; however, simply the variety and count cannot
determine the type or severity of periodontitis, which indi-
cated that immune responses against periodontal pathogens
may greatly affect the course of periodontal diseases, but the
mechanisms of periodontal bone resorption remain to be
established [1].
Periodontal bone resorption is induced by osteoclasts.
A balance between bone resorption by osteoclasts and bone
formation by osteoblasts determines the level of bone mass.
Receptor activator of nuclear factor-𝜅B ligand (RANKL), its
receptor RANK, and a decoy receptor osteoprotegerin (OPG)
are key molecules in regulating osteoclast differentiation,
recruitment, and function [2, 3]. RANKL is essential for the
complete differentiation of osteoclast precursor cells [4] and
plays a critical role in periodontal bone resorption [1]. In
this review, we have summarized the sources of RANKL in
periodontal disease and explored which factor may regulate
RANKL expression in this disease.
2. RANKL Expression in Periodontal Disease
RANKL, a polypeptide of 314 amino acids, encoded by the
gene TNFSF11 and expressed in a membrane-bound protein
or in secreted forms [5], is a member of the TNF cytokine
family and plays a very important role in periodontal bone
resorption. The level of RANKL mRNA has been reported to
be highest in advanced periodontitis compared with moder-
ate periodontitis or healthy groups. In addition, upregulated
RANKL levels are related to the number of P. gingavalis,
a major periodontal bacterium, in clinically obtained peri-
odontal tissue [6]. Later studies have demonstrated that bone
resorption can be decreased by inhibiting the RANK/RANKL
signal way during experimental periodontitis in rats [7, 8].
These results suggest that RANKL plays an important role
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RANKL is identified in lymphocytes, stromal cells,
and other types of cells [4, 9–11]. Liu et al. examined
RANKL mRNA expression at the cellular level using in situ
hybridization and found that RANKL mRNA was expressed
in inflammatory cells, mainly lymphocytes and macrophages
[11]. In addition, proliferating epithelium at the vicinity of
inflammatory cells expressed high levels of RANKL mRNA
[11]. Confocal microscopic analyses showed that both B cells
and T cells, but not monocytes or fibroblasts, are the major
cellular sources of RANKL in the bone resorptive lesion of
periodontal disease [10]. However, other cells may also be an
important source in this process because they can regulate
RANKL expression indirectly by excreting proinflammatory
cytokines, which can subsequently regulate the function of
lymphocytes.
2.1. B and T Lymphocytes Are the Primary Sources of RANKL
in the Bone Resorptive Lesion of Periodontal Disease. To
determine the cellular source of RANKL in bone resorptive
periodontitis, enzyme-linked immunosorbent assay (ELISA)
and double-color confocal microscopic analyses have been
used. Results of ELISA demonstrated that soluble RANKL
(sRANKL) production was significantly elevated in gingival
tissues with periodontal disease compared to healthy gingival
tissues. Confocal microscopic analyses showed that both B
andT cells, but notmonocytes or fibroblasts, were the cellular
source of RANKL in the bone resorptive lesions of peri-
odontal disease. Despite the potential involvement of other
factors in the bone destruction process, prominent expression
of RANKL by B and T cells in the periodontal disease
lesions seems to play a primary role in the augmentation
of bone resorption processes in this disease [10]. Further
study indicated that it is the activated but not na¨ıve B and T
lymphocytes that are the major sources of RANKL [10]. We
will introduce the RANKL expression of lymphocytes in the
following paragraph.
2.2. T Cells Stimulated by Periodontopathic Microorganisms
CanModulate Periodontal Bone Resorption throughUpregula-
tion of RANKL Production by an Adaptive Immune Response.
Kawai et al. reported that regulation of T-lymphocyte func-
tion can affect periodontal bone resorption in periodontal
disease [12–14]. Further studies indicate that T lympho-
cytes specific to A. actinomycetemcomitans are associated
with periodontal disease and periodontal bone resorption
in A. actinomycetemcomitans-infected rats occurred because
RANKL production was upregulated [14–16].
T cells isolated from the gingival tissue of A. actino-
mycetemcomitans-immunized P. pneumotropica+mice prolif-
erated in vitro and produced sRANKL in response to both
antigens presentation. However, gingival T cells isolated from
nonimmunized P. pneumotropica+ mice did not show such
a proliferative response to either A. actinomycetemcomitans-
antigen or P. pneumotropica-antigen presentation by antigen-
presenting cells, nor did they produce sRANKL [17]. These
results may also indicate that periodontopathic microorgan-
isms, such as A. actinomycetemcomitans, may induce bone
resorption by stimulating T cells and then upregulating
RANKL expression.
2.3. Different Types of CD4+ T Cells and RANKL Expressions
in Periodontal Tissues. Since the bacteria involved in peri-
odontal disease are extracellular pathogens, CD4+ T cells
appear to play amajor role in the antigen recognition of these
bacteria components. Many studies indicated this opinion:
Baker et al. have reported that bone loss decreased in CD4+
T cells deficient mice after oral infection by P. gingivalis,
but no change in mice deficient in CD8+ T cells or NK1+ T
cells [18]. Baker et al. demonstrated the importance of the
adaptive immune response, especially CD4+ T cells, in the
bone loss consequent to oral infection [18]. Another research
also indicated that CD4+ T cells were the predominant
cell type present in periodontitis gingival tissues, and they
expressed RANKL more than dendritic cells or monocytes
[19]. Uncommitted (naive) murine CD4+ T helper cells can
be induced to differentiate into T helper 1 (Th1), Th2, and
Th17 and regulatory T (Treg) phenotypes depending on the
local cytokine milieu. IL-27, a member of the IL-6/IL-12
family cytokines, was found to greatly inhibit bothmRANKL
expression and sRANKL secretion in CD4+ T cells activated
by T cell receptor ligation [20]. In contrast, in differentiated
Th17 cells, IL-27 much less efficiently inhibited RANKL
expression after restimulation [20]. Therefore, different types
of T cells may play different roles in RANKL expression
regulation.
2.3.1. Th1, Th2 Cells, and RANKL Expression in Periodontal
Tissues. In general, Th1-type cloned T-cells produce consis-
tently higher levels of RANKL than Th2-type T-cells, and
RANKL expression induced by TCR/CD28 costimulation is
suppressed in the presence of IL-4, suggesting that RANKL
is predominantly expressed on Th1-type T-cells [14]. In
experiments carried out with rat, T-cells, CD28, and TCR
stimulation could upregulate more RANKL expression than
TCR or CD28 stimulation alone, indicating that costimu-
latory signals are necessary to maximize RANKL expres-
sion. Furthermore, Th1 polarization by IL-12, in addition to
TCR/CD28 stimulation, enhanced the expression of RANKL
on the T cells, whereas Th2 polarization by IL-4 reduced
the RANKL expression on the same T-cells activated with
TCR/CD28 stimulation. Thus, Th1-type T-cells seem to be
potentiated to express RANKL as compared to Th2-type T-
cells. Costimulatory double signals from TCR and CD28 are
also required for the optimal expression of RANKL [14].
There is supportive, though not conclusive, evidence
that Th1 cells and their cytokines characterize early/stable
periodontal lesions [21]. Th1 cell cytokines, IFN-𝛾 and TNF-
𝛼, are related to RANKL expression. IFN-𝛾 is a major
product of activated T helper cells that can function as
a pro- or antiresorptive cytokine. IFN-𝛾 blunts osteoclast
formation through direct targeting of osteoclast precursors
but indirectly stimulates osteoclast formation and promotes
bone resorption by stimulating antigen-dependent T cell
activation and T cell secretion of the osteoclastogenic factors
RANKL and TNF-𝛼. Analysis of the in vivo effects of IFN-
𝛾 has been tested in 3 mouse models of bone loss including
ovariectomy, LPS injection, and inflammation via silencing
of TGF-𝛽 signaling in T cells models. The results revealed
that IFN-𝛾 has both direct antiosteoclastogenic and indirect
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proosteoclastogenic properties in vivo. Under the conditions
of estrogen deficiency, infection, and inflammation, the net
balance of these two opposing forces is biased toward bone
resorption. Inhibition of IFN-𝛾 signaling may thus represent
a novel strategy to simultaneously reduce inflammation and
bone loss in common forms of osteoporosis [22].
2.3.2. Th17 Cells and RANKL Expression in Periodontal Tis-
sues. In recent years, a new subset of CD4+ T-cells has been
discovered that helped to explain many of the discrepancies
in the classic Th1/Th2 model, and it has been termed “Th17”
based on its secretion of the novel proinflammatory cytokine
IL-17 [23]. Cardoso et al. have demonstrated the presence
of Th17 cells in the sites of chronic inflammation in human
periodontal disease. They collected gingival and alveolar
bone samples from healthy patients and patients with chronic
periodontitis and demonstrated elevated levels of IL-17, TGF-
𝛽, IL-1𝛽, IL-6, and IL-23 messenger RNA and protein in dis-
eased tissues aswell as the presence ofTh17 cells in the gingiva
from patients with periodontitis. Moreover, IL-17 and the
bone resorption factor RANKL were abundantly expressed
in the alveolar bones of diseased patients, in contrast to
low expression level in controls [24]. Ohyama et al. have
also reported that IL-17 is involved in periodontitis and the
IL-23/IL-17 pathway is frequently induced in periodontitis
lesions and that this pathway may therefore play an essential
role in periodontal biology [25].
The role of IL-17 in periodontal disease is controver-
sial. Whereas elevated IL-17 levels have been found in
humans with severe periodontal disease [26], Yu et al. have
recently reported that female C57BL/6J mice lacking the IL-
17 receptor (IL-17RAKO) are significantly more susceptible
to periodontal disease bone loss as a result of defects in the
chemokine-neutrophil axis [27]. Further study demonstrates
a gender-dependent effect of IL-17 signaling and indicates
that gender differences should be taken into account in the
preclinical and clinical study [28].
It is worth noticing that Th17 cells do not induce osteo-
clastogenesis in the absence of osteoblasts, which strongly
suggests that RANKL expressed on Th17 cells alone is not
sufficient to induce osteoclastogenesis: this is partly because
Th17 cells produce a small amount of IFN-𝛾, which counter-
balances the RANKL action [29].
2.3.3. Treg Cells andRANKLExpression in Periodontal Tissues.
The percentage of Foxp3+ cells is as low as 5% within the oth-
erwisemassive infiltration of RANKL+ lymphocytes found in
the diseased gingival tissues. In the peripheral blood lympho-
cytes can be stimulated with bacteria (A. actinomycetemcomi-
tans) in an antigen-dependent fashion; however, mRANKL
expression is expressed prominently in Foxp3 negative cells
and in Foxp3dim cells, not in Foxp3bright cells, which most
probably represent the presence of CD25/Foxp3 double-
positive cells. IL-10 suppressed both sRANKL and mem-
brane RANKL (mRANKL) expression by peripheral blood
mononuclear cells (PBMC) activated in vitro in a bacterial
antigen-specificmanner. Taken together, these results suggest
that Foxp3/CD25 double-positive Treg cells may play a role
in the downregulation of RANKL expression by activated
lymphocytes in periodontal disease tissues. These results
lead to the conclusion that the phenomenon of diminished
CD25+Foxp3+ Treg cells appears to be associated with the
increased RANKL+ T cells in the bone resorption lesions of
periodontal disease [30].
2.4. B-Cells and RANKL Expression in Periodontal Tissues.
More than 90% of B cells recovered from human periodontal
diseased tissues express RANKL, as opposed to about 54%
of T cells [10]. B cells do not seem to require the presence
of T cells to drive bone resorption. In a congenitally athymic
rat model of experimental periodontitis injected with donor
B cells, RANKL expression and the corresponding induction
of osteoclast differentiation increased in rats receiving B
cells from A. actinomycetemcomitans-immunized animals
compared to nonimmune B cells [31]. In a recent study, it
is suggested that RANKL expression is upregulated in B
cells in the adaptive immune response rather than in the
innate immune response to A. actinomycetemcomitans, and
preimmunization of animals with A. actinomycetemcomitans
leads to an enhanced B-cell response including increased
RANKL expression [32]. A recent in vitro study indicated that
toll-like receptors (TLRs) may play a role in B cell-mediated
RANKL-dependent periodontal bone resorption, and TLR4
and TLR9 diminish RANKL production, probably through
the induction of RANKL-expressing immune B cell apoptosis
[33].
2.5. Osteoblasts, Osteocytes, and RANKL Expression in Peri-
odontal Tissues. Mice with RANKL deficiency in osteoblast
lineage have showed some protection from bone loss induced
by ovariectomy as well as from joint destruction associated
with arthritis, whereas loss of RANKL inT cells did not confer
such protection, which indicated that RANKL expression by
osteoblast lineage plays an important role in bone resorption
[34]. Atkins et al. reported that RANKL expression was
related to the differentiation state of human osteoblasts
[35] and RANKL was expressed preferentially by immature
osteoblasts and the expression level decreased during their
maturation.
The idea that osteoblasts, or their progenitors, support
osteoclast formation by expressing the cytokine RANKL is
a widely held tenet of skeletal biology. But more recently
studies provide evidence that osteocytes, and not osteoblasts
or their progenitors, are the major source of RANKL driving
osteoclast formation in trabecular bone. Nakashima et al.
have reported that purified osteocytes express a much higher
amount of RANKL and have a greater capacity to support
osteoclastogenesis in vitro than both osteoblasts and bone
marrow stromal cells. Furthermore, the severe osteopetrotic
phenotype that they observed in mice lacking RANKL—
specifically, in osteocytes—indicates that osteocytes are the
major source of RANKL in bone remodeling in vivo [36].
However, femurs in mice lacking RANKL in osteocytes have
normal shapes, indicating that modeling of the metaphyseal
cortex of long bones is controlled by cells other than osteo-
cytes. Thus, the role of osteocyte-derived RANKL may be
limited to bone remodeling [37].
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Given the special anatomy of periodontal tissue, the role
of osteoblasts and osteocytes in periodontal diseases may be
different from other bone resorption diseases, because osteo-
clasts are formed at different skeletal sites for different pur-
poses.The results of the conditional RANKL deletion studies
show that the osteoclasts that form at these different sites
require different support cells in each case [37]. Specifically,
the finding that osteocyte-derived RANKL is not required
for tooth eruption or resorption of calcified cartilage during
endochondral bone formation shows that other cell types
must supply the RANKL required for osteoclast formation in
these processes [38].
2.6. Macrophage and RANKL Expression in Periodontal Tis-
sues. Although macrophage may be not the main source
of RANKL expression in periodontal disease [10], it can
influence RANKL expression through its pattern recognition
receptors (PRRs) and cytokines [39].
2.6.1. Macrophage PRRs and RANKL Expression in Periodon-
tal Tissues. Macrophages express a lot of PPRs, such as TLRs,
to recognize periodontal pathogens, and then induce a series
of intracellular signaling events, NF-𝜅B activation, and cul-
minating in expression of inflammatory mediators [39, 40].
Interestingly, the number of TLR2-expressing cells, but not of
TLR4-expressing cells, tends to increase linearly with gingival
inflammation. This may have to do with the fact that most
suspected periodontal pathogens preferentially activate TLR2
rather than TLR4. Indeed, P. gingivalis, T. forsythia, T. den-
ticola, Prevotella intermedia, Prevotella nigrescens, Capnocy-
tophaga ochracea, A. actinomycetemcomitans, Fusobacterium
nucleatum, and Veillonella parvula can all activate TLR2, but
only the last three can efficiently activate TLR4.The regulated
expressions of TLRs in the periodontium and their activation
by periodontal bacteria suggest that TLRs are potentially
major players in periodontitis. Whether TLRs are involved in
protective immunity or destructive inflammation (or both)
has yet to be elucidated. Their potentially ambivalent role
may be reflected in the studies that aim to correlate single
nucleotide polymorphisms of TLR genes with susceptibility
to periodontitis, which have been inconclusive when taken
together [41]. Clinical and experimental studies have iden-
tified that PRR-dependent recognition of P. gingivalis is an
initial step in host response to this organism, and TLRs have
emerged as a major group of PRRs involved in recognition
and signaling in the context of P. gingivalis exposure. Indeed,
experimental studies have identified that signaling through
TLR2 leads to oral bone loss in mice [42].
It has been reported that the innate immune response
promoted osteoclastogenic activity by activating RANKL via
TLR pathways [43]. Others reported that innate immune
recognition through TLR signaling is crucial for inflamma-
tory bone loss in response to infection by microorganisms
associated with chronic periodontal disease [44]. In a previ-
ous study, Rosen et al. showed that T. denticola lipooligosac-
charide (LOS) produced a concentration-dependent activa-
tion of NO and TNF-𝛼 in murine macrophages which was
inhibited by polymyxin B [45]. In their later study, they
showed that this activation is dependent on theTLR4-MyD88
signaling pathway [46].
Despite these reports, clinical studies employing a genetic
polymorphism approach are not in agreement regarding
major roles for TLRs in periodontal disease. Schro¨der et al.
[47] reported that a TLR4 polymorphism is associated with
periodontitis, while Folwaczny et al. [48] failed to observe
associations for TLR2 or TLR4. Thus it is likely that in
addition to TLRs, other unrecognized PRRs may contribute
to periodontal disease and host response to periodontal
pathogens. Baer et al. reported that Scavenger receptor A is
expressed by macrophages in response to P. gingivalis and
participates in TNF-𝛼 expression [49], which can upregulate
RANKL expression [50].
2.6.2. IL-1, TNF-𝛼, and RANKL Expression in Periodon-
tal Tissues. TNF-𝛼 potently increased osteoclast prolifera-
tion/differentiation in the presence of RANKL. This effect
was greatest when RANKL was present before exposure of
osteoclast precursor cells to TNF-𝛼. The resorptive activity
of osteoclasts generated by TNF-𝛼 in the absence of RANKL
was critically dependent upon IL-1, which was expressed
by lymphocyte-monocyte interaction [51]. Further study
indicated that IL-1 and LPS stimulate osteoclastogenesis
through two parallel events: direct enhancement of RANKL
expression and suppression of OPG expression, which is
mediated by PGE2 production [52].
In the process of periodontal disease, a key role for TNF-
𝛼 and IL-1 has been demonstrated, including regulation of
osteoclastogenesis in vitro and in vivo [10, 50, 53–55]. It
is noteworthy that during the progression of experimental
periodontitis, high levels of IL-1𝛽 and TNF-𝛼 have been
positively related to RANKL expression [56, 57]. Kawai et
al. have also reported that the concentrations of sRANKL
and IL-1𝛽 examined in the gingival tissue homogenates
were significantly elevated in the diseased gingival tissues
compared to healthy tissues [10]. Wei et al. reported that IL-1
mediates the osteoclastogenic effect by enhancing stromal cell
expression of RANKL and directly stimulating differentiation
of osteoclast precursors [50]. Fujihara et al. reported that
TNF-𝛼 enhances RANKL expression in gingival epithelial
cells via protein kinase A signaling [58].
2.7. Periodontal Ligament Fibroblasts, Gingival Fibroblasts,
and RANKL Expression. It had been reported that human
periodontal ligament cells stimulated with LPS inhibit osteo-
clastogenesis by producing more effective OPG than RANKL
through the induction of IL-1𝛽 and TNF-𝛼 [59]. Further
studies indicated that IL-1𝛼 stimulates osteoclast formation
by increasing the expression level of RANKL versus OPG
via ERK-dependent PGE2 production in PDL cells [9]. But
a more recent study reported that OPG was detected at high
levels in both fibroblast cultures, whereas RANKL could not
be detected [60].
Resorption of bone did not occur by the mononuclear
cells (MNCs) formed in the presence of fibroblasts, suggest-
ing that fibroblastsmay secrete inhibitors for bone resorption,
which leads to the osteoclast-like cells dysfunction. The
incapacity of the MNCs to resorb bone under the influence























Figure 1: B cells and T cells are primary RANKL expression cells
in periodontal bone resorption. Th17 cells can express RANKL;
however, RANKL expressed on Th17 cells alone is not sufficient
to induce osteoclastogenesis. Treg cells may play a role in the
downregulation of RANKL expression by activated lymphocytes in
periodontal disease tissues, but themechanism is unclear.Osteoblast
stromal cells may also express RANKL, but they play a role in
preventing bone resorption, since additional stimuli are required for
the formation of active osteoclasts. Although macrophage may not
be the main source of RANKL expression in periodontal disease, it
can influence RANKL expression through its cytokines.
of fibroblasts can be reversed by adding macrophage colony-
stimulating factor (M-CSF) andRANKL in the culturemedia.
These results suggest that tooth-associated fibroblasts may
still be able to trigger the formation of osteoclast-like cells,
but more importantly, they play a role in preventing bone
resorption, since additional stimuli are required for the
formation of active osteoclasts [60].
3. Conculsions
RANKL expression in periodontal tissues is a very compli-
cated process that involvesmany factors. RANKL is identified
in lymphocytes, stromal cells, and many other cell types in
periodontal tissues which play an important role in direct or
indirect regulatory roles. Cytokines such as IL-1𝛽 and TNF-
𝛼 can upregulate RANKL expression in periodontal cells and
increase osteoclast formation. Figure 1 summarizes themajor
cells and cytokines related to RANKL expression.
Therefore, discovering the pivotal step in RANKL expres-
sion may lead to a new insight into periodontal pathogenesis
and the development of a new target for periodontal therapy;
for example, we can prevent periodontal bone resorption
through RANKL expression inhibiting by moderating lym-
phocytes’ function or changing some cytokines’ level.
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